Worth reading
47Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-1377
¥ million (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales397,774¥ millionYear on year +5.8%Progress 24.8%
Operating profit2,465¥ millionYear on year -35.8%Progress 16.7%
Ordinary income3,810¥ millionYear on year -14.1%Progress 23.0%
Net income attributable to owners of the parent2,355¥ millionYear on year -29.8%Progress 18.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥36.24
Financial position at period-end
Total assets773,239¥ million
of which net assets 266,193 ¥ millionEquity ratio 34.4%vs. prior year-end -2.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceutical wholesale business ¥384,570 million (YoY +6.2%), Dispensing Pharmacy Business ¥24,977 million (YoY +1.5%), Pharmaceutical manufacturing and marketing business ¥2,953 million (YoY +0.2%), Other related businesses ¥1,507 million (YoY -7.2%)
Segment profitPharmaceutical wholesale business ¥3,110 million (YoY -25.1%), Dispensing Pharmacy Business ¥113 million (YoY -38.8%), Pharmaceutical manufacturing and marketing business ¥91 million (YoY +85.8%), Other related businesses ¥46 million (YoY -68.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥1,601,000 million (YoY +3.1%)
Operating profit¥14,800 million (YoY -10.9%)
Ordinary income¥16,600 million (YoY -0.2%)
Net income¥12,900 million (YoY -25.6%)
Revision to Earnings ForecastNo (unchanged)
Annual Dividend Forecast¥165 → ¥180（+9.1%）
Factors Behind Changes in Business Performance
The April 2026 drug price revision reduced drug prices on a drug-cost basis by 4.02%. Sales of anticancer drugs and specialty pharmaceuticals grew, but higher pharmaceutical procurement costs weighed on profit. In the dispensing pharmacy business, the number of prescriptions processed declined as long-term prescriptions became more common.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies (company name: —) / Excluded 0 companies (company name: —)
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥3 million, Gain on sale of investment securities ¥3 million / Extraordinary loss Losses on disposal of fixed assets ¥46 million, Loss on extinguishment of shares held in a merger ¥573 million, Other ¥1 million
Depreciation and amortization¥1,449 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End73,025,942
Treasury Shares at Period-End7,673,770
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥397,774 million (YoY +5.8%) |
| Operating profit | ¥2,465 million (YoY -35.8%) |
| Ordinary income | ¥3,810 million (YoY -14.1%) |
| Profit attributable to owners of the parent | ¥2,355 million (YoY -29.8%) |
| Net income per share | ¥36.24 |
| Equity ratio | End of the current fiscal period 34.4 / End of previous period 36.6 |
| Total assets | ¥773,239 million |
| Net assets | ¥266,193 million |
| Full-year earnings forecast | Net Sales ¥1,601,000 million (YoY +3.1%) / Operating profit ¥14,800 million (YoY -10.9%) / Ordinary income ¥16,600 million (YoY -0.2%) / Net income ¥12,900 million (YoY -25.6%) |
| Revision to Earnings Forecast | No (unchanged) |
| Annual Dividend Forecast | ¥165 → ¥180（+9.1%） |
| Segment revenue | Pharmaceutical wholesale business ¥384,570 million (YoY +6.2%), Dispensing Pharmacy Business ¥24,977 million (YoY +1.5%), Pharmaceutical manufacturing and marketing business ¥2,953 million (YoY +0.2%), Other related businesses ¥1,507 million (YoY -7.2%) |
| Segment profit | Pharmaceutical wholesale business ¥3,110 million (YoY -25.1%), Dispensing Pharmacy Business ¥113 million (YoY -38.8%), Pharmaceutical manufacturing and marketing business ¥91 million (YoY +85.8%), Other related businesses ¥46 million (YoY -68.8%) |
| Depreciation and amortization | ¥1,449 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥3 million, Gain on sale of investment securities ¥3 million / Extraordinary loss Losses on disposal of fixed assets ¥46 million, Loss on extinguishment of shares held in a merger ¥573 million, Other ¥1 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 73,025,942 |
| Treasury Shares at Period-End | 7,673,770 |
| Factors Behind Changes in Business Performance | The April 2026 drug price revision reduced drug prices on a drug-cost basis by 4.02%. Sales of anticancer drugs and specialty pharmaceuticals grew, but higher pharmaceutical procurement costs weighed on profit. In the dispensing pharmacy business, the number of prescriptions processed declined as long-term prescriptions became more common. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of market-leading products, including anticancer drugs and specialty pharmaceuticals, grew, while pharmaceutical procurement costs increased. In the dispensing pharmacy business, the number of prescriptions processed declined as long-term prescriptions became more common.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.